Hematology

Study Details Which Patients With MM, COVID-19 May Have Worse Prognosis

August 10, 2020

Article

A small study out of Sweden adds to context to the puzzle of how best to treat patients with multiple myeloma who contract COVID-19.

Reorganization of Sickle Cell Care Leads to Dramatic Drop in Hospitalizations

August 07, 2020

Article

Yale New Haven Hospital’s reorganization of its sickle cell disease program led patients to report feeling better off and needing fewer hospitalizations. However, the change left some with the disease still feeling unsatisfied.

Analysis Finds White, African American Patients Have Similar Access to Optimal MM Treatments

August 01, 2020

Article

New research suggests white and African American patients have similar rates of access to new treatments for multiple myeloma.

Severe Renal Impairment Worsens Outcomes in Multiple Myeloma

August 01, 2020

Article

A new study finds even if renal function is restored, patients who have severe renal impairment when diagnosed with multiple myeloma have lower overall survival rates.

Bristol Myers Squibb, bluebird bio Submit Second BLA for MM CAR T-Cell Treatment

July 30, 2020

Article

Bristol Myers Squibb and bluebird bio submitted a second Biologics License Application (BLA) to the FDA for idecabtagene vicleucel (ide-cel), the companies’ investigational B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell immunotherapy, indicated for adults with relapsed and refractory multiple myeloma (MM).

AJMC® in the Press, July 24, 2020

July 24, 2020

Article

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Persistent Immunoparesis Reduces OS Post Allo-SCT in Patients With MM

July 24, 2020

Article

A new study may have uncovered reasons why some patients with multiple myeloma have poor outcomes following allogeneic stem cell transplantation.

Cannabis May Be Safe, Potentially Effective Option for Pain for Sickle Cell Disease

July 23, 2020

Article

According to the study, vaporized cannabis, when compared with placebo, could be a safe and potentially effective way to address pain linked with sickle cell disease. While the decreases in pain were not statistically significant, the drug did significantly decrease pain interference in mood over a 5-day inpatient stay.

Janssen's Wildgust Breaks Down Bispecific Antibodies in Development for Non-Small Cell Lung Cancer and Multiple Myeloma

July 22, 2020

Article

During ASCO, Janssen presented results from the CHRYSALIS study on amivantimab, a bispecific antibody being developed to treat non–small cell lung cancer (NSCLC). The pharma giant, along with its parent company, Johnson & Johnson (J&J), had previously received a breakthrough therapy designation in December for teclistamab, another bispecific antibody indicated for potential treatment of multiple myeloma.

Study Outlines Treatment Outcomes in First Multiple Myeloma Relapse

July 18, 2020

Article

Only about one-third of patients with multiple myeloma who experience a very good partial response to therapy following first relapse, according to a new study.